Manufacturing strategy is a critical determinant of cost efficiency, quality, resilience, and operational agility across Life Sciences and Healthcare. Decisions on whether to manufacture internally or outsource directly affect cost structures, supply reliability, regulatory compliance, and the ability to scale or adapt to market demand. These choices are increasingly complex, as companies operate within extended manufacturing ecosystems involving CDMOs, CMOs, API manufacturers, and ingredient suppliers, alongside internal production capabilities.
Poorly structured make-or-buy decisions can result in capacity constraints, loss of control over quality or timelines, excessive fixed costs, or overdependence on external partners. Conversely, a well-defined manufacturing and sourcing strategy enables organizations to balance control and flexibility, manage risk, and align operations with long-term strategic objectives — whether supporting innovation, geographic expansion, or portfolio evolution.
We help organizations design evidence-based make-or-buy and outsourcing strategies that balance cost, quality, risk, and scalability. Our approach starts with a comprehensive assessment of internal manufacturing capabilities, cost structures, supply chain robustness, regulatory requirements, and strategic priorities. We then model alternative scenarios, evaluating the role of internal production versus external partners, including CDMOs, CMOs, API producers, and specialized ingredient manufacturers.
We support the selection and evaluation of outsourcing partners, assess contractual and governance models, and define sourcing strategies that ensure operational continuity and compliance. Our work also covers supplier diversification, capacity planning, and risk mitigation to strengthen supply chain resilience. By aligning manufacturing and outsourcing decisions with overall corporate strategy, we help clients improve flexibility, reduce risk, accelerate time to market, and ensure consistent delivery of high-quality products.
